Neurotech, Neuromodulation, Alzheimers.
companies Biogen and Eisai announced they were scrapping two phase 3 trials of the investigational anti-amyloid agent called aducanumab based on an interim “futility analysis”. In 2021, the companies cited new data from the studies and are seeking FDA approval again — basically, one of the studies